Список литературы
1. Sato Y., Okamoto K., Kawaguchi T., Nakamura F., Miyamoto H., Takayama T. Treatment Response Predictors of Neoadjuvant Therapy for Locally Advanced Gastric Cancer: Current Status and Future Perspectives. Biomedicines. 2022. 10(7). 1614. doi: 10.3390/biomedicines10071614.
2. Songun I., Keizer H.J., Hermans J., et al. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur. J. Cancer. 1999. 35(4). 558-562. doi: 10.1016/s0959-8049(98)00429-8.
3. Hartgrink H.H., van de Velde C.J., Putter H., et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur. J. Surg. Oncol. 2004. 30(6). 643-649. doi: 10.1016/j.ejso.2004.04.013.
4. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006. 355(1). 11-20. doi: 10.1056/NEJMoa055531.
5. Schuhmacher C., Gretschel S., Lordick F., et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J. Clin. Oncol. 2010. 28(35). 5210-5218. doi: 10.1200/JCO.2009.26.6114.
6. Alderson D., Cunningham D., Nankivell M., et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal ade–nocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol. 2017. 18(9). 1249-1260. doi: 10.1016/S1470-2045(17)30447-3.
7. Ychou M., Boige V., Pignon J.P., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J. Clin. Oncol. 2011. 29(13). 1715-1721. doi: 10.1200/JCO.2010.33.0597.
8. Al-Batran S.E., Hofheinz R.D., Pauligk C., et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016. 17(12). 1697-1708. doi: 10.1016/S1470-2045(16)30531-9.
9. Al-Batran S.E., Homann N., Pauligk C., et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019. 393(10184). 1948-1957. doi: https://doi.org/10.1016/S0140-6736(18)32557-1.
10. National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Gastric cancer (version 2.2022). www.nccn.org. Accessed February 11, 2023.
11. Zhang X., Liang H., Li Z., et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021. 22(8). 1081-1092. doi: 10.1016/S1470-2045(21)00297-7.
12. Al-Batran S.-E., Lorenzen S., Thuss-Patience P.C. et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophago-gastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. J. Clin. Oncol. 2022. 40 (16 suppl.). 4003. doi: 10.1200/JCO.2022.40.16_suppl.4003.
13. Hofheinz R.D., Hegewisch-Becker S., Kunzmann V., et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxali–platin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeits gemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int. J. Cancer. 2021. 149(6). 1322-1331. doi: 10.1002/ijc.33696.
14. Shitara K., Rha S.Y., Wyrwicz L.S. Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study. Ann. Oncol. 2023. 34. Iss. S2. S1316. doi: https://doi.org/10.1016/j.annonc.2023.10.075.
15. Janjigian Y., Al-Batran S.-E., Wainberg Z.A. Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): interim results of the global, phase 3 MATTERHORN study. Ann. Oncol. 2023. 34. Iss. S2. S1315. doi: https://doi.org/10.1016/j.annonc.2023.10.074.
16. Hofheinz R.D., Merx K., Haag G.M., et al. FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive ResectableEsophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group. J. Clin. Oncol. 2022. 40(32). 3750-3761. doi: 10.1200/JCO.22.00380.
17. Wang F.H., Zhang X.T., Li Y.F., et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun. (Lond). 2021. 41(8). 747-795. doi: 10.1002/cac2.12193.
18. Tokunaga M., Sato Y., Nakagawa M., et al. Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives. Surg. Today. 2020. 50(1). 30-37. doi: 10.1007/s00595-019-01896-5.
19. Zhai Y., Zheng Z., Deng W., et al. Interval time between neoadjuvant chemotherapy and surgery in advanced gastric cancer doesn’t affect outcome: A meta analysis. Front. Surg. 2023. 9. 1047456. doi: 10.3389/fsurg.2022.1047456.
20. Marano L., Carbone L., Poto G.E., et al. Extended Lympha–denectomy for Gastric Cancer in the Neoadjuvant Era: Current Status, Clinical Implications and Contentious Issues. Curr. Oncol. 2023. 30(1). 875-896. doi: 10.3390/curroncol30010067.
21. Fong C., Johnston E., Starling N. Neoadjuvant and Adjuvant Therapy Approaches to Gastric Cancer. Curr. Treat Options Oncol. 2022. 23(9). 1247-1268. doi: 10.1007/s11864-022-01004-9.
22. Marcisz-Grzanka K., Winiarek M., Pałucki J., et al. Safety and efficacy of the FLOT regimen in the Polish population — an ana–lysis of the prospective trial. Neoplasma. 2022. 69(6). 1445-1450. doi: 10.4149/neo_2022_220720N734.